Ashland Press Release
who enables release over time? we do.
date: July 15-17, 2025
location: Philadelphia, Pennsylvania
booth: Booth 312
Ashland solvers’ expertise in controlled release polymers results in tailored release profiles for injectable and oral drugs that meet your requirements for active pharmaceutical ingredient delivery.
Key Products presented at CRS 2025
- benecel™ xrf hpmc are fine particle grades designed for optimal performance in large-scale, high speed tableting. This product provides better powder flowability, produces robust tablets under high-throughput continuous manufacturing conditions and for challenging multi-layer sustained release tablets, and with lower nitrosamine levels, improves formulation stability by minimizing the potential for interaction between API and excipients that results in NDMA.
- viatel™ bioresorbable polymers control release over time. These polymers are the building blocks for developing long-acting injectable depots, an established technology to improve therapeutic efficacy and patient compliance. All viatel™ bioresorbable polymers can be custom produced.
- viatel™ ultrapure high-purity bioresorbable polymers are long-acting injectables and implants that offer improved stability and achieve longer, more consistent drug release profiles; they are better suited for sensitive drug compounds in long-acting injectables and implants (LAII).
- klucel™ xtend hpc has been shown to match the release profile of widely used hypromellose controlled release formulations at half the polymer concentration. The highly reduced polymer concentration achievable with klucel™ xtend HPC offers the possibility of smaller pills or higher dosage. This product is designed to deliver unsurpassed process versatility and release profile efficiency.
Ashland will also present posters at CRS 2025:
Poster Presentation 1
klucel™ xtend hydroxypropylcellulose (HPC) for dual active diabetic controlled release dosages
Learning Objectives:
- importance of dual-active controlled-release formulations for type II diabetes
- superior gel strength of klucel™ xtend in reducing burst effect in drug delivery
- klucel™ xtend HPC enables smaller tablets for improved efficacy and patient compliance
Dual-active controlled-release formulations for type II diabetes provide several benefits, including reduced dosing frequency, and improved patient compliance. Hydroxypropyl Methylcellulose (HPMC) usually comprises 20-30% of the weight of a tablet to achieve an acceptable release profile. This can result in large, hard-to-swallow tablets with complex processing. This study evaluates the process versatility and the tablet size reduction of klucel™ xtend HPC to match the release profiles of a bi-layer dosage of dual diabetic drugs.
This can result in large, hard-to-swallow tablets with complex processing. This study evaluates the process versatility and the tablet size reduction of klucel™ xtend HPC to match the release profiles of a bi-layer dosage of dual diabetic drugs.
by Kapish Karan – Global OSD Pharmaceutical R&D Leader, Life Sciences
Poster Presentation 2
advancing oral delivery of biologic drugs: overcome formulation challenges with permeation enhancers
Learning Objectives:
- importance of sodium caprate for oral biologic delivery
- effect of highly compressible sodium caprate in direct compression tableting
- how to evaluate sodium caprate intestinal permeability using Ussing chambers
Permeation Enhancers (PEs) are the leading strategy, with two approved oral peptide drugs RYBELSUS® and MYCAPSSA®. Sodium caprate (SC) is widely evaluated to improve the intestinal absorption of peptides via the paracellular and transcellular pathways. However, the poor flow and compression characteristics of SC have limited its utility in tablet processing. To overcome these limitations, a new process-engineered SC with improved flow and compaction to ease processing and yield more robust tablets than existing SC was developed and compared with commercially available SC.
by Quyen Schwing – Senior Pharmaceutical Team Leader/Research Scientist, Life Sciences
See the details of Ashland´s activities at CRS 2025 here
Source: Ashland, website CRS 2025 Annual Meeting and Exposition
